Chlorprotixen - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Neuroleptics

Included in the formulation

Truksal®

pills inwards

H. Lundbeck A / S Denmark

Chlorprotixen

pills inwards

DRUGSTORE IN PLUS, LLC Russia

Chlorprotixen Zentiva

pills inwards

Zentiva c.s. Czech Republic

АТХ:

N.05.A.F.03 Chlorprotixen

Pharmacodynamics:

Has antipsychotic effect due to blockade of dopamine D₂receptors of the mesocortical and mesolimbic system.

Acts as a sedative by blockade of adrenoreceptors of the reticular formation of the brain stem.

Has antiemetic effect, blocking dopamine D₂receptors of the trigger zone of the vomiting center.

It causes hyperthermia due to blockade of hypothalamus dopamine receptors.

It has moderate antihistaminic and M-cholinoblocking action. Reduces blood pressure. Increases the pain threshold.

Pharmacokinetics:

After oral ingestion, up to 12% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 90%.

Penetrates through the blood-brain and placental barrier, excreted in breast milk. Metabolism in the liver.

The half-life is 8-12 hours. Elimination with feces and kidneys in the form of metabolites.

Indications:

It is used for the treatment of endogenous psychoses, reactive psychiatric disorders.Used to enhance the effect of antihistamines and analgesics. It is used as an antiemetic for Meniere's disease, radiation and chemotherapy. Used in the composition of the lytic mixture for the purpose of artificial hypothermia, as well as in the complex treatment of itching dermatoses.

ICD-10

V.F10-F19.F10.4 Mental and behavioral disorders caused by alcohol use - abstinent state with delirium

V.F20-F29.F20 Schizophrenia

V.F20-F29 Schizophrenia, schizotypic and delusional disorders

V.F20-F29.F21 Chrysotile disorder

V.F20-F29.F22 Chronic delusional disorders

V.F20-F29.F25 Schizoaffective disorder

V.F20-F29.F29 Inorganic psychosis, unspecified

V.F50-F59.F51.2 Sleep and wakefulness disorder inorganic etiology

VI.G90-G99.G93.4 Encephalopathy, unspecified

XII.L20-L30.L20.8 Other atopic dermatitis

XII.L20-L30.L28.0 Simple chronic lichen

XII.L20-L30.L29 Itching

XVIII.R00-R09.R05 Cough

XIX.S00-S09.S06 Intracranial injury

XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified

Contraindications:

Poisoning with alcohol, barbiturates, pheochromocytoma, children under 6 years of age, diseases of the hematopoiesis, individual intolerance.

Carefully:

Atherosclerosis of cerebral vessels, respiratory failure (bronchial asthma, emphysema), prostatic hyperplasia, epilepsy, peptic ulcer and duodenal ulcer, Reye syndrome, cholelithiasis and urolithiasis, hypersensitivity.

Pregnancy and lactation:

Pregnancy and lactation: recommendations for FDA - Category C. During pregnancy and during lactation, the use of the drug is contraindicated. If it is not possible to abolish the use of chlorprotixen during pregnancy, minimal maintenance doses are applied, with temporary cancellation for the period of labor to prevent atropine-like effects in newborns.

Dosing and Administration:

Use in children

Inside, with neuroses: 5-30 mg per day; at psychoses - on 10-200 mg a day.

Adults

Inside, at one time: 10-15 mg at night with neuroses; at psychoses - on 100-600 mg a day for the night; with skin itching - 15-100 mg per day for 4 doses.

The highest daily dose: 600 mg.

The highest single dose: 600 mg.

Side effects:

Central and peripheral nervous system: akathisia, rarely - parkinsonian syndrome, dystonic extrapyramidal reactions, thermoregulation disorders, tardive dyskinesia, in single cases convulsive syndrome develops.

Hemopoietic system: agranulocytosis, leukopenia.

The cardiovascular system: tachycardia, orthostatic hypotension.

Digestive system: dry mouth, dyspeptic disorders, increased appetite and weight gain.

Dermatological reactions: hyperhidrosis, photosensitization, skin pigmentation.

Sense organs: opacity of the lens, accommodation paresis, blurred vision.

Urinary system: delay urination.

Reproductive system: violations of the menstrual cycle, gynecomastia, decreased libido and potency.

Allergic reactions.

Overdose:

Convulsions, tachycardia, oppression of consciousness, extrapyramidal symptoms, arterial hypotension, hyperthermia, coma.

Treatment is symptomatic.

Interaction:

When used simultaneously with drugs that depress the central nervous system (hypnotics, benzodiazepines, non-opioid and opioid analgesics, tricyclic antidepressants, anesthetics), the antihypertensive effect and inhibition of the central nervous system increase.

MAO inhibitors contribute to the development of extrapyramidal disorders (due to a slowdown in the metabolism of chloroprotoxen in the liver).

Reduces the absorption of the drug with the simultaneous use of antacid agents - should be able to withstand an interval of 4 hours.

Chlorprotixen reduces the effects of levodopa with simultaneous application.

Special instructions:

With long-term use - monitoring the blood formula, electrocardiogram indicators, liver function, blood pressure.

Excluded is the use of alcohol during treatment with chlorprotixene and within 5 days after discontinuation of the drug.

When hyperthermia appears, it is recommended that the drug be withdrawn.

In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

Instructions

Chlorprotixen (Chlorprothixenum)